SEC Tracker
Get the app

Rapport Therapeutics RAPP

Rapport Therapeutics offers $ Convertible Senior Notes due 2032

Securities offering

Form
424B5
Filed
Importance
Routine
  1. Notes bear interest at % per year, payable semiannually
  2. Conversion rate is shares of common stock per $1,000 principal
  3. Redemption possible on or after Dec 6, 2030 if stock price meets conditions
  4. Notes are general unsecured obligations

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Rapport Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  2. Ocugen OCGN public float $279M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025